Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Blueprint Medicines Corporation stock

Own Blueprint Medicines Corporation stock in just a few minutes.

Blueprint Medicines Corporation is a biotechnology business based in the US. Blueprint Medicines Corporation shares (BPMC) are listed on the NASDAQ and all prices are listed in US Dollars. Blueprint Medicines Corporation employs 429 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Blueprint Medicines Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BPMC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Blueprint Medicines Corporation share price

Use our graph to track the performance of BPMC stocks over time.

Blueprint Medicines Corporation shares at a glance

Information last updated 2021-04-30.
52-week range$56.00 - $125.61
50-day moving average $97.81
200-day moving average $102.00
Wall St. target price$116.31
PE ratio 17.3703
Dividend yield N/A (0%)
Earnings per share (TTM) $5.59

Buy Blueprint Medicines Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Blueprint Medicines Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Blueprint Medicines Corporation under- or over-valued?

Valuing Blueprint Medicines Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Blueprint Medicines Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Blueprint Medicines Corporation's P/E ratio

Blueprint Medicines Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Blueprint Medicines Corporation shares trade at around 17x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Blueprint Medicines Corporation's EBITDA

Blueprint Medicines Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $315.3 million.

The EBITDA is a measure of a Blueprint Medicines Corporation's overall financial performance and is widely used to measure a its profitability.

Blueprint Medicines Corporation financials

Revenue TTM $793.7 million
Operating margin TTM 38.89%
Gross profit TTM $466.5 million
Return on assets TTM 15.91%
Return on equity TTM 32.45%
Profit margin 39.55%
Book value $25.44
Market capitalisation $5.7 billion

TTM: trailing 12 months

Shorting Blueprint Medicines Corporation shares

There are currently 3.3 million Blueprint Medicines Corporation shares held short by investors – that's known as Blueprint Medicines Corporation's "short interest". This figure is 4.2% up from 3.1 million last month.

There are a few different ways that this level of interest in shorting Blueprint Medicines Corporation shares can be evaluated.

Blueprint Medicines Corporation's "short interest ratio" (SIR)

Blueprint Medicines Corporation's "short interest ratio" (SIR) is the quantity of Blueprint Medicines Corporation shares currently shorted divided by the average quantity of Blueprint Medicines Corporation shares traded daily (recently around 383155.63380282). Blueprint Medicines Corporation's SIR currently stands at 8.52. In other words for every 100,000 Blueprint Medicines Corporation shares traded daily on the market, roughly 8520 shares are currently held short.

However Blueprint Medicines Corporation's short interest can also be evaluated against the total number of Blueprint Medicines Corporation shares, or, against the total number of tradable Blueprint Medicines Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Blueprint Medicines Corporation's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Blueprint Medicines Corporation shares in existence, roughly 60 shares are currently held short) or 0.0564% of the tradable shares (for every 100,000 tradable Blueprint Medicines Corporation shares, roughly 56 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Blueprint Medicines Corporation.

Find out more about how you can short Blueprint Medicines Corporation stock.

Blueprint Medicines Corporation share dividends

We're not expecting Blueprint Medicines Corporation to pay a dividend over the next 12 months.

Blueprint Medicines Corporation share price volatility

Over the last 12 months, Blueprint Medicines Corporation's shares have ranged in value from as little as $56 up to $125.61. A popular way to gauge a stock's volatility is its "beta".

BPMC.US volatility(beta: 0.73)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Blueprint Medicines Corporation's is 0.7314. This would suggest that Blueprint Medicines Corporation's shares are less volatile than average (for this exchange).

Blueprint Medicines Corporation overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc. ; CStone Pharmaceuticals; Genentech, Inc. ; and F.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site